MTOR and overgrowth syndrome: As sirolimus targets cellular proliferation, survival and stemness via mTOR inhibition, its observed effect on some vascular tumors and vascular malformations, including overgrowth syndromes, may be attributed to its action on these primitive populations within these VAs.